The aim of this study was to repeat a previous audit, performed from 2009 to 2013, for the cohort of 2018 to determine how the resistance rates in urinary pathogens in women over 18 years of age have changed. A secondary aim of the study was to use resistance data from a different UK hospital in the same year to compare differences in resistance rates across different geographic locations
Study design
This was a retrospective study of all positive urine cultures grown from female patients attending two different hospitals in the year 2018. Resistance patterns were analysed.
Results
The resistance rate to co-amoxiclav continues to increase with amoxicillin retaining high resistance patterns. There are some significant differences in resistance patterns between the different locations.
Conclusion
Antimicrobial resistance is a significant problem in the UK particularly in antibiotics used to treat UTI. These patterns can vary across different geographical locations and over time; therefore, up-to-date knowledge of local anti-biotic resistance is essential when making an appropriate prescription choice.
Organisation WHO. Antimicrobial resistance: global report on surveillance 2014. Geneva: WHO, 2014.
2.
BrairAToozs-HobsonP, et al.
Local audit: how tightly should we police antibiotic prescribing for urinary tract infection and how should we modify national policy?Post Reprod Health2015;
21: 151–157.
3.
CourtenayMCastro-SanchezEFitzpatrickM, et al.
Tackling antimicrobial resistance 2019–2024 – the UK’s five-year national action plan. J Hosp Infect2019;
101: 426–427.
4.
EnglandPH. English surveillance programme for antimicrobial utilisation and resistance (ESPAUR). Public Health England, 2018–2019.
5.
CarJ.Urinary tract infections in women: diagnosis and management in primary care. BMJ2006;
332: 94–97.
6.
ChinTLMcNultyCBeckC, et al.
Antimicrobial resistance surveillance in urinary tract infections in primary care. J Antimicrob Chemother2016;
71: 2723–2728.
7.
MalcolmWFletcherEKavanaghK, et al.
Risk factors for resistance and MDR in community urine isolates: population-level analysis using the NHS Scotland Infection Intelligence Platform. J Antimicrob Chemother2018;
73: 223–230.
8.
FlemingABarryLByrneS, et al.
Antimicrobial susceptibility of long term care facility and general practice urine samples in patients 65 years and older: an observational study. Eur J Public Health2017;
27: 307–312.
KhasriyaRBarcellaWDe IorioM, et al.
Lower urinary tract symptoms that predict microscopic pyuria. Int Urogynecol J2018;
29: 1019–1028.
13.
VellingaAGalvinSDuaneS, et al.
Intervention to improve the quality of antimicrobial prescribing for urinary tract infection: a cluster randomized trial. CMAJ2016;
188: 108–115.
14.
HolmbergLBomanG.Pulmonary reactions to nitrofurantoin. 447 cases reported to the Swedish Adverse Drug Reaction Committee 1966–1976.Eur J Respir Dis1981;
62: 180–189.
15.
LivaniosKKarampiESSotiriouA, et al.
Nitrofurantoin-induced acute pulmonary toxicity. Respirol Case Rep2016;
4: 25–27.
16.
SundqvistMGranholmSNaseerU, et al.
Within-population distribution of trimethoprim resistance in Escherichia coli before and after a community-wide intervention on trimethoprim use. Antimicrob Agents Chemother2014;
58: 7492–7500.
17.
GraningerW.Pivmecillinam – therapy of choice for lower urinary tract infection. Int J Antimicrob Agents2003;
22(Suppl 2): 73–78.
18.
BollestadMGrudeNSolhaugS, et al.
Clinical and bacteriological efficacy of pivmecillinam treatment for uncomplicated urinary tract infections caused by ESBL-producing Escherichia coli: a prospective, multicentre, observational cohort study. J Antimicrob Chemother2018;
73: 2503–2509.
19.
SilverLL.Fosfomycin: mechanism and resistance.Cold Spring Harb Perspect Med. Epub ahead of print 6 January 2017. DOI: 10.1101/cshperspect.a025262
20.
DewarSReedLCKoernerRJ.Emerging clinical role of pivmecillinam in the treatment of urinary tract infection in the context of multidrug-resistant bacteria. J Antimicrob Chemother2014;
69: 303–308.
ChenCChenYWuP, et al.
Update on new medicinal applications of gentamicin: evidence-based review. J Formos Med Assoc2014;
113: 72–82.
23.
PopkinBMD’AnciKERosenbergIH.Water, hydration, and health. Nutr Rev2010;
68: 439–458.
24.
ScholesDHootonTMRobertsPL, et al.
Risk factors for recurrent urinary tract infection in young women. J Infect Dis2000;
182: 1177–1182.
25.
NielsenAFWalterS.Epidemiology of infrequent voiding and associated symptoms.Scand J Urol Nephrol Suppl1994;
157: 49–53.
26.
SuSBWangJNLuCW, et al.
Prevalence of urinary tract infections and associated factors among pregnant workers in the electronics industry. Int Urogynecol J Pelvic Floor Dysfunct2009;
20: 939–945.
27.
CrannSECunninghamSAlbertA, et al.
Vaginal health and hygiene practices and product use in Canada: a national cross-sectional survey. BMC Womens Health2018;
18: 52.
KranjčecBPapešDAltaracS.D-mannose powder for prophylaxis of recurrent urinary tract infections in women: a randomized clinical trial. World J Urol2014;
32: 79–84.
30.
LeeBSBhutaTSimpsonJM, et al.
Methenamine hippurate for preventing urinary tract infections. Cochrane Database Syst Rev2012;
10: CD003265.
31.
RobinsonDToozs-HobsonPCardozoL.The effect of hormones on the lower urinary tract. Menopause Int2013;
19: 155–162.
32.
PerrottaCAznarMMejiaR, et al.
Oestrogens for preventing recurrent urinary tract infection in postmenopausal women. Cochrane Database Syst Rev2008;
2: CD005131.
33.
YangBFoleyS.First experience in the UK of treating women with recurrent urinary tract infections with the bacterial vaccine Uromune. BJU Int2018;
121: 289–292.
34.
English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR). Public Health England, 2018–2019.
35.
CarlsenSKrallSPXuKT, et al.
Sensitivity of urinary pathogens for patients discharged from the emergency department compared with the hospital antibiogram. BMC Emerg Med2019;
19: 50.
36.
Kornfält IsbergHMelanderEHedinK, et al.
Uncomplicated urinary tract infections in Swedish primary care; etiology, resistance and treatment. BMC Infect Dis2019;
19: 155.
37.
AlósJI.[Epidemiology and etiology of urinary tract infections in the community. Antimicrobial susceptibility of the main pathogens and clinical significance of resistance].Enferm Infecc Microbiol Clin2005;
23(Suppl 4): 3–8.
38.
SahooKCTamhankarAJSahooS, et al.
Geographical variation in antibiotic-resistant Escherichia coli isolates from stool, cow-dung and drinking water. Int J Environ Res Public Health2012;
9: 746–759.
39.
TuemKBGebreAKAteyTM, et al.
Drug resistance patterns of Escherichia coli in ethiopia: a meta-analysis. Biomed Res Int2018;
2018: 4536905.
40.
BryceAHayADLaneIF, et al.
Global prevalence of antibiotic resistance in paediatric urinary tract infections caused by Escherichia coli and association with routine use of antibiotics in primary care: systematic review and meta-analysis. BMJ2016;
352: i939.
41.
OteoJCamposJLázaroE, et al.
Increased amoxicillin-clavulanic acid resistance in Escherichia coli blood isolates, Spain. Emerg Infect Dis2008;
14: 1259–1262.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
